ストックスクリーナーアプリを入手
5.13
1.58%
0.08
アフターアワーズ：
5.03
-0.10
-1.95%
前日終値:
$5.05
開ける：
$5.13
24時間の取引高:
322.24K
Relative Volume:
0.56
時価総額：
$1.60B
収益：
$391.87M
当期純損益:
$-441.45M
株価収益率:
-2.773
EPS:
-1.85
ネットキャッシュフロー:
$-301.21M
1週間 パフォーマンス:
-3.02%
1か月 パフォーマンス:
+0.59%
6か月 パフォーマンス:
-43.75%
1年 パフォーマンス:
-61.22%
1日の値動き範囲:
$5.04
$5.23
1週間の範囲:
$4.97
$5.348
52週間の値動き範囲:
$4.32
$13.70
Alvotech Stock (ALVO) Company Profile
ALVO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
5.13 | 1.57B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
125.82 | 55.71B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.59 | 49.38B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.11 | 44.89B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.21 | 35.96B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
487.25 | 21.36B | 3.08B | 1.24B | 1.07B | 25.61 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-09 | 開始されました | Barclays | Underweight |
| 2025-11-04 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-10-14 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-23 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-14 | 開始されました | UBS | Buy |
| 2024-01-29 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-10-20 | アップグレード | Citigroup | Sell → Neutral |
| 2023-09-21 | 開始されました | Barclays | Equal Weight |
| 2022-09-07 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-09-06 | ダウングレード | Citigroup | Buy → Sell |
| 2022-07-26 | 開始されました | Citigroup | Buy |
すべてを表示
Alvotech (ALVO) 最新ニュース
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged ... - Bluefield Daily Telegraph
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Alvotech Secures USD 100 Million Senior Term Loan to Enhance Liquidity and Support R&D Initiatives - Quiver Quantitative
Alvotech Secures Term Loan Facility of USD 100 Million - The Manila Times
Alvotech (NASDAQ:ALVO) Trading 2.9% HigherShould You Buy? - MarketBeat
Alvotech Investor News: Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action InvestigationALVO - PR Newswire
Alvotech announced that it has received $100 million in funding - marketscreener.com
The Technical Signals Behind (ALVO) That Institutions Follow - Stock Traders Daily
ALVO Investor News: If You Have Suffered Losses in Alvotech - GlobeNewswire
Alvotech Files Notification with CSSF Regarding Changes in Own Shares - Quiver Quantitative
Changes in company's own shares - marketscreener.com
Alvotech : Changes in company's own shares - marketscreener.com
Alvotech : Acquisition or disposal of the issuer's own sharesALVOTECH - marketscreener.com
EV Market: Why Alvotech stock is favored by top institutionsMarket Sentiment Review & Growth Oriented Trading Recommendations - moha.gov.vn
Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Why Bolt Projects Holdings Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket - Benzinga
Alvotech (NASDAQ:ALVO) Short Interest Down 41.1% in December - MarketBeat
Is Alvotech stock near bottom after declineSwing Trading Watchlist & Build Wealth Brick by Brick With Us - bollywoodhelpline.com
Alvotech Investor News: Rosen Law Firm Encourages Alvotech Inves - GuruFocus
Alvotech (NASDAQ:ALVO) Trading Up 6.8%Time to Buy? - MarketBeat
Alvotech (ALVO): Firm reaffirms 2025 growth outlook - MSN
What analysts say about Alvotech Z45 stockCapital Gains Strategies & Outstanding Investment Returns - earlytimes.in
Alvotech Begins European Rollout of First-Ever Simponi Biosimilar Gobivaz - TipRanks
Why Alvotech (ALVO) Is Down 8.5% After Securing a 2026 US Entry Window for AVT06 - simplywall.st
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma - Sahm
Alvotech announces European launch of biosimilar to Simponi - MSN
Alvotech/Advanz First to Launch Golimumab Biosimilar Worldwide - Pearce IP
Alvotech’s Financial Calendar for 2026 - The Manila Times
Alvotech : Financial Calendar for 2026 - marketscreener.com
Alvotech rolls out first Simponi biosimilar across Europe - The Pharma Letter
Alvotech Launching Gobivaz Biosimilar in Europe - marketscreener.com
New Simponi lookalike drug rolls out in Europe with NHS backing - Stock Titan
Alvotech Announces Launch of Gobivaz® (AVT05) in the UK Following NHS England Tender Award - Quiver Quantitative
Alvotech, Teva reach settlement and license agreement with Regeneron for AVT06 - MSN
Fund Flows: Is Alvotech stock supported by strong fundamentalsMarket Risk Analysis & Real-Time Volume Analysis Alerts - moha.gov.vn
Alvotech (ALVO): Firm Reaffirms 2025 Growth Outlook - Finviz
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action InvestigationALVO - ACCESS Newswire
Assessing Alvotech (NasdaqGM:ALVO)’s Valuation After FDA Setback and 2025 Guidance Cut - simplywall.st
Big Money Moves: Why retail investors favor Alvotech stockEarnings Miss & Short-Term Trading Opportunity Alerts - ulpravda.ru
Volume Recap: Why Alvotech Equity Warrant stock remains resilient2025 Market WrapUp & Long Hold Capital Preservation Tips - ulpravda.ru
Alvotech, Teva secure US settlement with Regeneron for Eylea biosimilar launch - Indian Pharma Post
Can Alvotech stock beat market expectations this quarterMarket Activity Recap & Capital Efficient Trading Techniques - ulpravda.ru
Is Alvotech stock gaining market shareJuly 2025 Macro Moves & Community Trade Idea Sharing Platform - ulpravda.ru
Alvotech to raise $100M via convertible bonds, provides 2026 forecast - MSN
Alvotech price target lowered to $10 from $14 at Morgan Stanley - MSN
How interest rate cuts could boost Alvotech Equity Warrant stockQuarterly Trade Summary & Free Reliable Trade Execution Plans - ulpravda.ru
Can Alvotech stock sustain revenue growthRecession Risk & Stock Portfolio Risk Management - ulpravda.ru
Dip Buying: Is Alvotech stock near bottom after decline2025 Retail Activity & Technical Buy Zone Confirmation - Улправда
Partners Alvotech, Teva eye 2026 Eylea biosimilar launch in US with Regeneron settlement - Fierce Pharma
Alvotech and Teva Settle With Regeneron on U.S. Launch Timing for Eylea Biosimilar AVT06 - TipRanks
Is Alvotech stock attractive after correctionStop Loss & AI Optimized Trading Strategy Guides - Bölüm Sonu Canavarı
Alvotech (ALVO) 財務データ
収益
当期純利益
現金流量
EPS
8.30%
0.62%
大文字化:
|
ボリューム (24 時間):